

1 **RESEARCH REPORT**

2

3 **Outcome determinants of snakebites in North Bihar, India: a prospective hospital based study**

4

5 Takanungsang Longkumer, Lois J Armstrong, Philip Finny

6

7 Duncan Hospital, A Unit of Emmanuel Hospital Association, Raxaul, East Champaran District,

8 Bihar, India

9

10 Correspondence to: Lois Armstrong, Email: loisjarmstong@gmail.com

11

12 **J Venom Res** (2017), Vol 8, 00-00

13

14 **Received:** 06 March 2017 | **Revised:** 26 June 2017 | **Accepted:** 28 June 2017 | **Published:** 28 June
15 2017

16

17 **©Copyright** The Author(s). This is an open access article, published under the terms of the
18 Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0>). This license permits non-commercial use, distribution and reproduction of this article,
19 provided the original work is appropriately acknowledged, with correct citation details.
20

21

22

23

24

25

26

27

28

29

30

31

32

33

1 **ABSTRACT**

2

3 Bihar is the state with the third largest number of snakebite deaths per year in India. This
4 prospective, one-year study of 608 snakebites provides the first data from Bihar on determinants of
5 unfavourable outcomes in snakebites. Any delay in reaching hospital raised the risk of a snakebite
6 patient for an unfavourable outcome [OR 8.88, CI 2.04-38.8]. Attending a traditional practitioner
7 prior to presenting to the hospital was the only specific, significant delay [OR 3.52, CI 1.26-9.7].
8 Prevention of unfavourable outcomes occurred by presenting to hospital in less than 1.5 hours [OR
9 0.23, CI 0.052-1.0]. Motorbike was the best mode of transport [OR 0.37, CI 0.12-1.1]. Other risk
10 factors were patients aged under 15 years [OR 3.79, CI 1.57–9.12] and bites to the upper limb [OR
11 2.47, CI 1.01-6.04]. Patients who were envenomated had a higher risk of unfavourable outcome, if
12 referred due to antivenom being unavailable [OR 12.2, CI 1.49-100]. To save lives, it is imperative
13 that measures to reduce delays in getting patients to hospital must be included in snakebite
14 management, alongside continued availability of antivenom and assisted ventilation.

15

16 **KEY WORDS:** Snakebite, unfavourable outcomes, risk factors, delays, traditional practitioners,
17 motorbikes

18

19 **INTRODUCTION**

20

21 In Bihar, 4500 deaths are attributed to snakebite each year. Thus, it is the state of India with the
22 third largest number of snakebite deaths after Uttar Pradesh and Andhra Pradesh (David et al,
23 2012). However, there is little documented evidence regarding the situation of snakebites within the
24 state of Bihar.

25

26 Duncan Hospital in East Champaran District of Bihar sees around 500 snakebites per year. Being at
27 the Indo-Nepal border, patients from North Bihar as well as the plains of South Nepal, present to the
28 hospital with snakebites. A retrospective chart audit was carried out of the 367 people who
29 presented to Duncan Hospital, Raxaul, in 2011 with snakebites, bites by unknown agent (but
30 suspected to be a snakebite), and signs of envenomation with no known bite. The highest number of
31 cases was in 11–15 year olds, with neurotoxic envenomation occurring in 13.3%. No
32 coagulopathies were seen. Of those with neurotoxic symptoms, 51% also had local bite site tissue
33 damage or inflammation consistent with a cobra bite (Unpublished data). The venomous snakes in
34 the region were believed to be cobras and kraits.

35

1 The closest snakebite research, geographically, is from the Chitwan district, Nepal and (Pandey,
2 2007) and the Eastern Terai (plains) of Nepal (Sharma et al, 2004a). They have both reported
3 predominantly neurotoxic envenomation due to cobras and kraits. The community study by Sharma
4 et al (2004b) showed 80% of the deaths were occurring prior to reaching hospital. Attending a
5 traditional practitioner prior to hospitalisation was a significant risk factor for mortality and
6 travelling to the hospital on a motorbike, decreased the risk of dying. (Sharma et al, 2004a or
7 2004b). Due to the similar geography and socioeconomic status to the area the Duncan Hospital
8 services, this data has provided the most useful comparative data.

9
10 The envenomation rate in the community study on the Eastern Terai of Nepal showed an
11 envenomation rate of 52% (Sharma et al, 2004a). Duncan Hospital admissions had an
12 envenomation rate of 13.3% in the unpublished, 2011 audit. This marked difference required further
13 investigation. The hypothesis was that there are either many non-venomous snakebites, and/or,
14 many people are dying prior to reaching health facilities. A prospective hospital based study is
15 reported here and a community based study is planned for the near future.

16
17 This is a prospective study to look specifically into mortality and unfavourable outcomes in snake bites.
18 The data on issues relating to human–snake conflict and snakebites has been published elsewhere
19 (Longkumer et al, 2016). The information collected in this study will help to provide an evidence-based,
20 community and hospital, education program to reduce the incidence of snakebite deaths.

21

22 **MATERIAL AND METHODS**

23

24 This prospective study was carried out at Duncan Hospital from 1 July 2012 to 30 June 2013.
25 Duncan Hospital is a secondary level, 200-bed hospital with 10 Intensive Care beds and at the time
26 of this study had five ventilators available. All patients during this time period who were admitted
27 alive with: a history of snakebite, a bite by an unknown agent, or symptoms of snake envenomation
28 without a known snakebite, were asked to take part in the study. Patients who dead on arrival with a
29 history of snakebite or symptoms of envenomation were also included.

30

31 Routine management protocol at the time of the study included:

32

- 33 • Injection of tetanus toxoid for all patients;
- 34 • 10 vials of ASV (Snake antivenom) to patients showing signs of neurotoxic envenomation,
35 with a premedication of hydrocortisone and pheniramine maleate;

- 1 • Patients with inflammation and swelling at the bite site for more than 24 hours were given
2 ampicillin/cloxacillin and metronidazole.

3
4 If the patient was given less than 10 vials of ASV at a prior hospital/clinic, the balance was given on
5 arrival at Duncan Hospital. The ASV used is the Indian manufactured quadrivalent antivenom.

6
7 Descriptive information was collected on: the patient; the snakebite – site of bite, time of bite, time
8 to hospital; the environment where the snakebite occurred. Dead snakes brought to the hospital
9 were photographed and then preserved in formalin. At the end of the study these snakes were
10 identified to the species level by a herpetologist. Information was also obtained on delays in
11 reaching the hospital, first aid prior to arrival and any treatment given in a referring hospital. The
12 symptoms on arrival at the hospital were recorded along with the details of management throughout
13 their hospital stay and their outcome on discharge.

14
15 Unfavourable outcomes were defined by one of the following; (i) patients who were dead on arrival
16 at hospital; (ii) died in hospital; (iii) referred to other centres due to serious complications that were
17 likely to cause their death; (iv) patients who were discharged from the hospital because they had not
18 regained consciousness after 72 hours, or showed symptoms of brain death, and were expected to
19 die. This composite outcome variable was chosen to capture all the poor outcomes in one variable
20 and was used assess for Odds Ratios for two groups: the set of persons bitten by snakes and the
21 subset of persons who were envenomated. Only univariate analysis has been used as the small size
22 of the outcome variable provided sparse data for many variables.

23
24 The study was explained to patients and their relatives in a relevant language and verbal consent
25 was taken. In the situation where the patient was unable to give consent (dead on arrival or
26 intubated), the consent was sought from the attending relative. A written copy of the study
27 explanation was made available in Hindi for those who can read.

28
29 The data were collected on a written proforma and then entered in EpiData. Analysis was done in
30 Epi Data Analysis and Vassarstats (www.vassarstats.net). Ethics permission was obtained from
31 Emmanuel Hospital Association Research and Ethics Committee (Proposal number 77).

32 33 **RESULTS**

34
35 From 1 July 2012 to 30 June 2013, 608 people were recruited in the study as per Figure 1. The six

1 excluded cases were: scorpion bite (1); spider bite (1); late presentation-6days (1); snake's blood
2 splashed into the eyes while killing a snake (1); afraid but not actually bitten by a snake (2). The
3 descriptive data of the 608 patients studied is presented in Table 1. The odds ratios for unfavourable
4 outcomes have been included where adequate data was available. The descriptive data of the 76
5 envenomated patients is presented in Table 2. The odds ratios for unfavourable outcomes have been
6 included where adequate data was available.

7
8 Unfavourable outcomes accounted for 21 patients: 14 dead on arrival at hospital; four who died in
9 hospital; and three who left against medical advice at relatives request and were expected to die due
10 to Hypoxic Ischaemic Encephalopathy. The causes of death for those who dies in hospital were:
11 Hypoxic Ischaemic encephalopathy (HIE) [2]; cardiogenic shock (1); Acute Respiratory Distress
12 Syndrome [1]. The overall evenomation rate is 12.6%; case fatality rate is 2.9%; unfavourable
13 outcome rate is 3.4%.

14
15 The snakes that were identified in the preserved collection were Common Wolf Snake (*Lycodon*
16 *aulicus*) – 21, Spectacled Cobra (*Naja naja*) – 11, Common Kukri Snake (*Oligodon arnensis*) – one.
17 Four *Naja naja* were associated with a syndrome of neurotoxic envenomation with local tissue
18 damage as per Figure 2. The *Lycodon aulicus* and *Oligon arnensis* specimens were not associated
19 with any envenomation syndrome.

20 21 **DISCUSSION**

22
23 This study provides the first data regarding determinants of unfavourable outcomes in snakebites
24 from the state of Bihar.

25
26 The under-fifteen age group had a significantly higher risk of unfavourable outcomes due to snake
27 envenomation. This may be because the snake will inject the same amount of venom in both the
28 adult and paediatric age group, which in children will mean a higher concentration of venom in
29 their smaller body. It may also be related to the need to first inform an adult about the bite and then
30 wait for the adult to bring them to hospital, another factor which increases the risk of unfavourable
31 outcomes.

32
33 Bites to the upper limb have a higher risk of an unfavourable outcome. This has not been noted in
34 the literature previously. One possible hypothesis is that venom may reach the central circulation
35 more rapidly from upper limbs than from the lower extremities but no data has been found to
36 support this.

1

2 Arrival at hospital within 1.5 hours of the bite appears to be protective against an unfavourable
3 outcome. There was no unfavourable outcome if the patient arrived in less than one hour of the bite.
4 The rapid demise caused by respiratory paralysis requires an even more rapid treatment with both
5 ASV and assisted ventilation. Thus, it is important that any reasons for delay are understood and
6 remedied.

7

8 Organising transport was reported to be a much bigger problem than organising money or
9 organising relatives to accompany a snakebite patient. Motorbikes were the most common means of
10 transport and appear to be more protective than other forms of transport. This is in line with the
11 study found from the nearby eastern region of Nepal. (Sharma et al, 2004a). Advising people to
12 come by motorbike, especially if there is no other readily available transport, would be likely to
13 prevent deaths. (Sharma et al, 2013) The advice should involve three people travelling on the
14 motorbike: the driver, the patient, and a person who can hold on to the patient should they become
15 paralysed.

16

17 The unavailability of ASV resulted in people travelling longer distances to reach definitive
18 treatment. Although this is not statistically significant in the odds ratios for snakebite patients, it
19 was when the envenomated patients are evaluated for determinants that contribute to unfavourable
20 outcomes. During July/August 2012 there was limited supply of ASV in Nepal and this resulted in
21 extra cases of snakebite presenting to the hospital.

22

23 Attending a traditional practitioner prior to attending hospital also increases the risk of an
24 unfavourable outcome. This was the only question asked regarding traditional practitioners so this
25 practice needs to be understood further so that relevant education can be implemented to prevent
26 this delay leading to unnecessary deaths.

27

28 The syndromes present; neurotoxic, with or without local tissue damage, match with the species of
29 venomous snakes locally described as being in the region, Cobra and Krait. This study provides
30 evidence of *Naja naja* being responsible for the syndrome of neurotoxicity with tissue damage in
31 North Bihar. Patients have a much better ability to identify cobras than other snakes (Longkumer et
32 al, 2016) and so it is not surprising that 20 out of 45 patients who described being bitten by a cobra,
33 also presented with neurotoxic envenomation and tissue damage. The haemotoxic envenomation is
34 the only one seen in the seven years of the longest serving physician at Duncan Hospital. This
35 patient presented with bleeding from the mouth and nose. He had been given four vials of snake

1 antivenom (ASV) at a peripheral hospital in Nepal and his clotting parameters were normal on
2 arrival. The patient came from the foothill region in Nepal (3 to 4 hours travel) suggesting the snake
3 may have been one of the pit vipers from that region.

4
5 Two non-venomous snakes (Common Wolf Snake and Common Kukri Snake) were brought to the
6 hospital during the study. Ongoing, unpublished work on snakes seen in the area now documents
7 seven other non-venomous species and a recent study from the plains of Nepal also has recorded
8 numerous non-venomous species (Sharma et al, 2016). This may partly explain the low
9 envenomation rate seen at Duncan Hospital.

10
11 The other possible reason for low envenomation rates is deaths due to snakebite occurring the
12 community before presentation to hospital. The 14 patients who were dead on arrival at the hospital,
13 may support this. Community studies in Nepal and West Bengal have shown there are many
14 victims of snakebites who never attend hospital facilities. (Sharma et al, 2004a; Majumder et al,
15 2014).

16
17 Unfavourable outcomes were positively associated with the need for mechanical ventilation in
18 analysis relating to the entire cohort. Vellore, in southern India, has a different spectrum of snakes,
19 but there is also an increase in mortality associated with mechanical ventilation (David et al, 2012).
20 Neurotoxic envenomation management requires not only ASV, but also timely intubation and
21 appropriate ventilation to prevent hypoxia, which is the ultimate killer.

22

23 **Limitations and further directions**

24 Despite working in a resource-limited setting, this study begins to provide data on an unstudied
25 problem in Bihar. As a hospital based study, there will always be a bias in the data collected and so
26 a community study would be important, especially to discover information on patients that never
27 reach hospital. The available health facilities and the skill of their staff, needs to be assessed.

28

29 This study was only designed to collect data for one year and so there are limitations due sample
30 size of the data. A larger study, which allowed for multivariate analysis of data, could assist in
31 clearly pinpointing the problems causing delays.

32

33 No data were collected on the practices of traditional practitioners and the reasons why people seek
34 care from them. During this study, Nepal ran out of ASV and so the data collection for this study
35 became a larger than expected. However, this may have provided evidence that the unavailability of

1 ASV has contributed to unfavourable outcomes.

2

3 **CONCLUSIONS**

4

5 This study provides a basis to pursue further the neglected problem of snakebite among the huge,
6 rural population of Bihar, India. Delays in seeking the definitive treatment (ASV and assisted
7 ventilation) are the major contributors and need to be better understood to provide the necessary
8 education, training and resources. The practice of attending traditional practitioners needs to be
9 better understood to prevent this delay in seeking definitive treatment increase the risk of an
10 unfavourable outcome. Arrival at hospital in less than one hour from the bite is the determinant that
11 eliminates the risk of an unfavourable outcome. 72% of patients completely recovered from their
12 envenomation but this percentage needs to approach 100%, for this very treatable incident.

13

14 **COMPETING INTERESTS**

15

16 None declared.

17

18 **ACKNOWLEDGEMENTS**

19

20 The authors thank Mr Vishal Santra and the teaching staff for snake identification, Dr Priscilla
21 Robinson for training in the use EpiData software, junior doctor colleagues for assisting with data
22 collection, and Lydia, Joyce and Milly for assistance with data entry. This research received no
23 specific funding from the public, commercial or not-for-profit sector.

24

25 **REFERENCES**

26

27 David S, Matathia S, Christopher S. 2012. Mortality Predictors of Snake Bite Envenomation in
28 Southern India - A Ten-Year Retrospective Audit of 533 Patients. *J Med Toxicol*, 8, 118–123.

29 Longkumer T, Armstrong L, Santra V and Finny P. 2016. Human, snake, and environmental factors
30 in human - snake conflict in North Bihar - a one-year descriptive study. *Christian Journal for Global
31 Health*, 3, 36-45.

32 Majumder D, Sinha A, Battacharya SK, Ram R, Dasgupta U, and Ram A. 2014. Epidemiological
33 Profile of Snake Bite in 24 Parganas District of West Bengal with Focus on Underreporting of
34 Snake Bite Deaths. *Indian Journal of Public Health*, 58, 17-21.

35 Mohapatra B, Warrell DA, Suraweena W, et al. 2011 Snakebite mortality in India: a nationally rep-
36 resentative mortality survey. *PLoS Negl Trop Dis*, 5, e1018.

- 1 Pandey DP. 2007. Epidemiology of Snakebites Based on Field Survey in Chitwan and Nawalparasi
2 Districts, Nepal. *J Med Toxicol*, 3,164-168.
- 3 Sharma SK, Khanal B, Pokhrel P, Khan A and Koirala S. 2003. Snakebite re-appraisal of the situa-
4 tion in Eastern Nepal. *Toxicon*, 41, 285-289.
- 5 Sharma S, Chappuis F, Jha N, Bovier PA, Loutan L, and Koirala S. 2004a. Impact of snake bites
6 and determinants of fatal outcomes in southeastern Nepal. *Am J Trop Med Hyg*, 71, 234-238.
- 7 Sharma SK, Koirala S and Dahal G. 2004b. Clinico-Epidemiological Features of Snakebite: A
8 Study in Eastern Nepal. *Tropical Doctor*, 34, 20-22.
- 9 Sharma SK, Bovier P, Jha N, Alirol E, Loutan L and Chappuis F. 2013. Effectiveness of Rapid
10 Transport of Victims and Community Health Education on Snake Bite Fatalities in Rural Nepal.
11 *Am J Trop Med Hyg*, 89, 145-50.
- 12 Sharma SK, Kuch U, Hode P, Bruhse L, Pandey DP, Ghimire A, Chappuis F, Alivol E. 2016. Use
13 of Molecular Diagnostic Tools for the Identification of Species Responsible for Snakebite in Nepal:
14 A Pilot Study. *PLoS Negl Trop Dis* 10, e0004270.

15

16

17

18

19

20

21

22

23

24

25

26

27


28

29

30

1 **Figure 1.** Flow chart of study participants

2



3

4

5

6

7

8

9

10

11

12

13

14

15


16

17

18

1 **Figure 2.** Flow chart of Envenomation syndromes seen in the patients who showed signs of
2 envenomation.

3
4



5
6
7
8
9
10
11
12
13
14
15
16
17

1 **Table 1.** Descriptive data of snakebites and determinants for unfavourable outcomes of snakebite in
 2 Duncan Hospital, North Bihar, India. [N = number of patient for whom data were available. # =
 3 Patients/relatives were first asked if they had any delay in reaching hospital. Then they were asked what the
 4 delays were; there may have been more than one specific cause for the delay.]

5
6

Variable (N)	n (%)	OR	CI
Gender (608)			
Male	321	1.2	0.46-3.28
Female	277	-	
Age (608)			
<15	143	3.79	1.57-9.12
15+	465	-	
Country (605)			
India	351	1.09	0.40-3.12
Nepal	254	-	
Time to hospital (580)			
<1.5 hour	200	0.23	0.052-1.0
>=1.5 hour	380	-	
Bite site part (576)			
Upper Limb	178	2.47	1.01-6.04
Lower Limb	391	0.28	0.11-0.71
Trunk	1	-	
No known site	6	-	
Transport (533)			
By foot	13	7.5	1.5-37
Motorbike	314	0.37	0.12-1.1
Cycle rickshaw	25	undefined	
Four wheeled vehicles	212	1.45	0.52-4.06
Tanga	11	3.83	0.46-32
Other	14	-	
Delays (505)			
Any Delay #	262	8.88	2.04-38.7
Organising money	0	-	
Org Transport	82	0.44	0.12-1.56
Floods	1	-	
Traffic Jam	0	-	
Bad roads	0	-	
No ASV	47	3.77	0.49-29.1
Distance	59	1.93	0.68-5.47
Org relatives	8	2.08	0.24-17.9
Traditional Practitioner	47	3.52	1.26-9.7
Other	45	-	
Management (60)			
Assisted Ventilation	33	7.05	0.72-354

7
8
9
10
11
12

1 **Table 2.** Descriptive data of envenomated patients and determinants of unfavourable outcomes of
 2 snakebite in Duncan Hospital, North Bihar, India. [N = number of patient for whom data was available
 3 # = Patients/relatives were first asked if they had any delay in reaching hospital. Then they were
 4 asked what the delays were; there may have been more than one specific cause for the delay.
 5 * = All were unfavourable outcomes]

Variable (N)	n (%)	OR	CI
Gender (75)			
Male	39(52)	1.75	0.62-4.9
Female	36(48)	-	
Age (75)			
<15	28(37)	2.39	0.85-6.7
15-30	25(33)	0.57	0.18-1.8
30+	23(30)	0.62	0.19-1.9
Time to hospital (64)			
<1.5 hour	11(17)	0.56	0.17-2.4
>=1.5 hour	54(84)	1.77	0.34-9.1
Bite site part (72)			
Upper Limb	29(40)	1.7	0.57-4.98
Lower Limb	36(50)	0.74	0.25-2.17
Trunk	1(1.4)	-	
No known site	6 (8.3)	-	
Transport (66)			
Motorbike	22(33)	0.87	0.25-3.01
Four wheeled vehicle	44(67)	2.05	0.62-6.81
Delays			
Any Delay #	58	0.49	0.09-2.5
Org Transport	9	1.6	0.29-8.58
No ASV	19	12.2	1.49-100
Distance	19	0.96	0.29-3.14
Traditional Practitioner	19	0.69	0.21-2.24
Management (75)			
Assisted Ventilation	28(37)	0.12	0.014-1.08
Surgical debridement	13(17)	-	
Syndrome (75)			
Neurotoxic alone	28(37)	0.78	0.27-2.27
Neurotoxic plus tissue damage	32(43)	0.21	0.06-0.67
Neurotoxic but no data about bite site	9(12)	*	
Haemotoxic	1(1.3)	-	

7